NCT01979523 2026-03-19
Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
14 trialsNCT01587352 2026-03-18
Vorinostat in Treating Patients With Metastatic Melanoma of the Eye
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03070392 2026-03-17
Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma
Immunocore Ltd
Phase 2 Completed
NCT02068586 2026-03-16
Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma
Thomas Jefferson University
Phase 2 Active not recruiting
NCT05907954 2026-03-16
(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma
IDEAYA Biosciences
Phase 2 Active not recruiting
NCT05199584 2026-03-05
A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Endeavor Biomedicines, Inc.
Phase 2 Completed
NCT06414590 2026-03-03
Neoadjuvant Tebentafusp for Uveal Melanoma
Thomas Jefferson University
Phase 2 Recruiting
NCT06070012 2026-02-27
Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma
University of Pittsburgh
Phase 2 Recruiting
NCT03417739 2026-02-25
A Phase II Study of BVD-523 in Metastatic Uveal Melanoma
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT02517736 2026-02-17
O-Mel-Sora
University Hospital, Caen
Phase 2 Completed
NCT04552223 2026-02-11
Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma
University of Miami
Phase 2 Completed
NCT04645680 2026-01-30
DIET
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT06717126 2026-01-16
OCULE-01
iOnctura
Phase 2 Active not recruiting
NCT05524935 2026-01-08
Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting